A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  International Journal of Radiation Oncology, Biology, Physics

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1278-3218(00)00060-3PMID 10924966
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The potential for sparing of parotids and escalation of biologically effective dose with intensity-modulated radiation treatments of head and neck cancers: a treatment design study.

  2000cited by this paper
• Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer.

  1999cited by this paper
• Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma.

  1999cited by this paper
• Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer.

  1999cited by this paper
• Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study.

  1998cited by this paper
• Radiotherapy and concurrent chemotherapy for the treatment of locally advanced head and neck squamous cell carcinoma.

  1998cited by this paper
• Altered fractionation trials in head and neck cancer.

  1998cited by this paper
• Comprehensive irradiation of head and neck cancer using conformal multisegmental fields: assessment of target coverage and noninvolved tissue sparing.

  1998cited by this paper
• A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer.

  1997cited by this paper
• 106 Conventional radiotherapy as primary treatment of squamous cell carcinoma of the head and neck. A randomized multicenter study of 5 versus 6 fractions per week-report from the Dahanca 7 trial

  1997cited by this paper
• Toxicity antagonists in cancer therapy

  1997cited by this paper
• Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial.

  1997cited by this paper
• Combined-modality therapy for head and neck cancer.

  1997cited by this paper
• Role of accelerated fractionated irradiation for supraglottic carcinoma: assessment of results.

  1997cited by this paper
• Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: an interim report. CHART Steering Committee.

  1996cited by this paper
• Randomized clinical trial on accelerated 7 days per week fractionation in radiotherapy for head and neck cancer. Preliminary report on acute toxicity.

  1996cited by this paper
• Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)

  1995cited by this paper
• Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13.

  1995cited by this paper
• Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas.

  1995cited by this paper
• Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.

  1995cited by this paper
• Accelerated versus conventional fractionation in the postoperative irradiation of locally advanced head and neck cancer: influence of tumour proliferation.

  1992cited by this paper
• Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy.

  1992cited by this paper
• Accelerated fractionation radiotherapy for laryngeal cancer, acute, and late toxicity.

  1992cited by this paper
• Concomitant boost technique using accelerated superfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck

  1992cited by this paper
• Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma.

  1991cited by this paper
• ASTRO plenary: interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: results from Radiation Therapy Oncology Group protocol 8313.

  1991cited by this paper
• Dose-response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracts: preliminary report of radiation therapy oncology group protocol 83-13.

  1990cited by this paper
• Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer.

  1990cited by this paper
• Accelerated hyperfractionation radiation therapy for carcinoma of the nasopharynx. Techniques and results

  1989cited by this paper
• Designing clinical trials for two-sided multiple comparisons with a control.

  1989cited by this paper
• Local control of oropharyngeal carcinoma after two accelerated hyperfractionation radiation therapy schemes.

  1988cited by this paper
• Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (preliminary report) by the Radiation Therapy Oncology Group (RTOG).

  1987cited by this paper
• Twice-a-day radiation therapy for supraglottic carcinoma.

  1986cited by this paper
• Biologic basis for altered fractionation schemes

  1985cited by this paper
• Twice‐a‐day radiation therapy for cancer of the head and neck

  1985cited by this paper
• The randomization and stratification of patients to clinical trials.

  1974cited by this paper
• Evaluation of survival data and two new rank order statistics arising in its consideration.

  1966cited by this paper

• Outcomes of Reduced Elective Nodal Radiation Dose and Volume for Laryngeal, Hypopharyngeal, and p16‐Negative Oropharyngeal Cancers

  2025cites this paper
• Principles and Paradigms of De-Escalated Elective Nodal Irradiation: Boldly Going Towards an Inflection Point in Head and Neck Radiotherapy.

  2025cites this paper
• Complete Pathological Response of Human Papillomavirus (HPV)-Related Oropharyngeal Carcinoma After Primary Treatment With Stereotactic Radiotherapy: A Case Report

  2025cites this paper
• Effect of radiotherapy on the biomechanical preparation of different instrumentation kinematics.

  2025cites this paper
• Accelerated fractionated radiotherapy with twice-daily treatment shows promise in treating dogs with locally advanced gingival squamous cell carcinoma.

  2025cites this paper
• Feasibility study of synchronously increasing dose of multi-shell structure to improve stereotactic ablation radiotherapy central dose of large volume locally advanced gastrointestinal stromal tumors using cyberKnife

  2025cites this paper
• Multicentric Cross-Sectional Survey to Assess the Variation of Fractionation Strategies Used in the Management of Head and Neck Cancers in the Asian Region (INNOCENCE-ASIA)

  2025cites this paper
• Evaluating Clinical Factors Including HPV Clearance on Survival Outcomes in HPV+ Oropharyngeal Carcinoma

  2025cites this paper
• Expert consensus on the prevention and treatment of radiochemotherapy-induced oral mucositis

  2025influential citation
• NAVIGATING THE CHALLENGES OF IMMUNOTHERAPY AS A NEOADJUVANT TREATMENT FOR LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK: A REVIEW OF THE EVIDENCE FROM THE LITERATURE.

  2025cites this paper
• Enhancing X-ray Activated Photodynamic Therapy with Supported Lipid Bilayer-Coated Radioluminescent Nanoparticles.

  2025cites this paper
• Post-radiation hypothyroidism in patients with head and neck tumors: An overview assessment

  2025cites this paper
• Radiation Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline.

  2024cites this paper
• Radiation-induced skin injury in the head and neck region: pathogenesis, clinics, prevention, treatment considerations and proposal for management algorithm

  2024cites this paper
• De-Escalation Strategies in HPV-Associated Oropharynx Cancer: A Historical Perspective with Future Direction

  2024cites this paper
• Time-to-Treatment Delays and Their Prognostic Implications in Pharyngeal Cancer—An Exploratory Analysis in Western Romania

  2024cites this paper
• Concomitant Boost With Six Fractions of Radiation a Week in Locally Advanced Head and Neck Cancer Patients: A Prospective Study

  2024cites this paper
• Does adaptive radiotherapy for head and neck cancer favorably impact dosimetric, clinical, and toxicity outcomes?: A review

  2024cites this paper
• Oral glutamine: Is there a role in the amelioration of radiation-induced mucositis? A prospective case-control study at a tertiary care centre in North India.

  2024cites this paper
• Conventional chemoradiation versus accelerated chemoradiation: A prospective study in oropharyngeal cancer

  2024cites this paper
• Osteoradionecrosis Rates Following Head and Neck Radiotherapy: Beyond the Numbers.

  2024cites this paper
• Leave No Cancer Behind: The Conformal Hypofractionation Era and Head and Neck Cancer.

  2024cites this paper
• Long-Term Outcomes Following Definitive or Adjuvant Proton Radiotherapy for Adenoid Cystic Carcinoma

  2024cites this paper
• Latin American Consensus on the Treatment of Head and Neck Cancer.

  2024cites this paper
• Emerging Radiotherapy Technologies for Head and Neck Squamous Cell Carcinoma: Challenges and Opportunities in the Era of Immunotherapy

  2024cites this paper
• A Comparative Prospective Study Between Conventional Chemo-Radiotherapy and Pure Accelerated Radiotherapy With Concurrent Chemotherapy for the Treatment of Locally Advanced Head and Neck Cancer

  2023cites this paper
• An umbrella review exploring the effect of radiotherapy for head and neck cancer patients on the frequency of jaws osteoradionecrosis.

  2023cites this paper
• Has innovations in radiotherapy for head and neck cancer improved patients curability?

  2023cites this paper
• A New Prognostic Instrument for Predicting the Probability of Completion of Cisplatin during Chemoradiation for Head and Neck Cancer

  2023cites this paper
• Does Diabetes Mellitus Increase Radiotherapy/ Chemoradiotherapy Acute Toxicities?

  2023cites this paper
• Definitive Radiotherapy in Locally Advanced Head and Neck Squamous Cell Cancer with Clinical Extranodal Extension

  2023cites this paper
• CONCOMITANT BOOST IRRADIATION WITH WEEKLY LOW-DOSE CHEMOTHERAPY IN LOCALLY ADVANCED HEAD AND NECK CANCERS

  2023cites this paper
• Hypofractionated Radiotherapy followed by Hypofractionated Boost with weekly concurrent chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Results of A Prospective Phase II Study (GASTO-1049).

  2023cites this paper
• Clinical Outcomes of Radiotherapy for Stage 1 Glottic Carcinoma: Comparing Accelerated Hyperfractionation and Once-daily Fractionation

  2023cites this paper
• The relevance of ototoxicity induced by radiotherapy

  2023cites this paper
• Response assessment of post-treatment head and neck cancers to determine further management using NI-RADS (Neck Imaging Reporting and Data System): a subgroup analysis of a randomized controlled trial

  2023cites this paper
• A Comparison of the Toxicities in Patients With Locally Advanced Head and Neck Cancers Treated With Concomitant Boost Radiotherapy Versus Conventional Chemoradiation

  2023cites this paper
• Mechanisms involved in cancer stem cell resistance in head and neck squamous cell carcinoma

  2023cites this paper
• Oropharyngeal Carcinoma with a Special Focus on HPV-Related Squamous Cell Carcinoma

  2023cites this paper
• Once upon a time in oncology – will we definitely win a war against cancer? Critical review of the progresses in cancer therapies

  2023cites this paper
• Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.

  2023cites this paper
• Low Post-Treatment Quality of Life and the High Incidence of Pain Are Common and Significantly Exacerbated in Depressed Head and Neck Patients Treated with Definitive Accelerated Radiotherapy

  2023cites this paper
• Machine Learning-Based Multiomics Prediction Model for Radiation Pneumonitis

  2023cites this paper
• Multi‐institutional study of clinical outcomes of patients with head and neck cancer presenting with cN3 disease

  2023cites this paper
• Efficacy of ketamine mouthwash in the management of oral and pharyngeal toxicity associated with head and neck chemoradiotherapy: protocol for a phase II, Simon’s two-stage trial

  2023cites this paper
• A Century of Fractionated Radiotherapy: How Mathematical Oncology Can Break the Rules

  2022cites this paper
• Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus-Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy.

  2022cites this paper
• Kurative Radiochemotherapie von Kopf-Hals-Tumoren

  2022cites this paper
• The Normal, the Radiosensitive, and the Ataxic in the Era of Precision Radiotherapy: A Narrative Review

  2022cites this paper
• Nutritional Status Impacts Quality of Life in Head and Neck Cancer Patients Undergoing (Chemo)Radiotherapy: Results from the Prospective HEADNUT Trial

  2022cites this paper
• Oral cavity adjuvant therapy (OCAT) -a phase III, randomized controlled trial of surgery followed by conventional RT (5 fr/wk) versus concurrent CT-RT versus accelerated RT (6fr/wk) in locally advanced, resectable, squamous cell carcinoma of oral cavity.

  2022cites this paper
• Long-term update of NRG/RTOG 0522: a randomized phase III trial of concurrent radiation and cisplatin with or without cetuximab in locoregionally advanced head and neck cancer.

  2022cites this paper
• Accelerated Fractionation Radiotherapy and Chemotherapy Might Improve Loco-Regional Control of Head and Neck Squamous Cell Carcinoma

  2022cites this paper
• Compensation for radiotherapy treatment interruptions due to a cyberattack: An isoeffective DVH‐based dose compensation decision tool

  2022cites this paper
• Escalating a Biological Dose of Radiation in the Target Volume Applying Stereotactic Radiosurgery in Patients with Head and Neck Region Tumours

  2022cites this paper
• Clinicopathology and Treatment Patterns of Head and Neck Cancers in Ethiopia

  2022cites this paper
• The role of concomitant chemoradiotherapy versus radiation alone in T1-3N0 HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma.

  2022cites this paper
• A phase II randomized double blinded trial evaluating the efficacy of curcumin with pre-operative chemoradiation for rectal cancer

  2022cites this paper
• Results from a prospective, randomised study on (accelerated) preoperative versus (conventional) postoperative radiotherapy in treatment of patients with resectable squamous cell carcinoma of the oral cavity - The ARTSCAN 2 study.

  2021cites this paper
• Stereotactic radiotherapy as planned boost after definitive radiotherapy for head and neck cancers: Systematic review

  2021cites this paper
• Hypo-fractionated radiotherapy with concurrent chemotherapy for locoregional recurrence of non-small cell lung cancer after complete resection: A prospective, single-arm, phase II study (GASTO-1017).

  2021cites this paper
• Evaluation approach for whole dose distribution in clinical cases using spherical projection and spherical harmonics expansion: spherical coefficient tensor and score method.

  2021cites this paper
• Hypofractionated Intensity Modulated Radiation Therapy With Concurrent Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer: A Phase II Prospective Clinical Trial (GASTO1011).

  2021cites this paper
• Low‐dose preoperative radiation, resection, and reduced‐field postoperative radiation for soft tissue sarcomas

  2021cites this paper
• Predictive modelling of hypoxic head and neck cancers during fractionated radiotherapy with gold nanoparticle radiosensitisation.

  2021cites this paper
• Retreatment in locally recurrent nasopharyngeal carcinoma: Current status and perspectives

  2021cites this paper
• Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trial.

  2021cites this paper
• Low‐risk human papilloma virus positive oropharyngeal cancer with one positive lymph node: Equivalent outcomes in patients treated with surgery and radiation therapy versus surgery alone

  2021cites this paper
• Radiation therapy in head and neck cancer

  2021cites this paper
• Accelerated Fractionation With Concomitant Boost vs. Conventional Radio-chemotherapy for Definitive Treatment of Locally Advanced Squamous Cell Carcinoma of the Head-and-Neck (SCCHN)

  2021cites this paper
• Delay to surgery after neoadjuvant chemotherapy in head and neck squamous cell carcinoma affects oncologic outcomes

  2021cites this paper
• Accelerated Fractionation Plus Chemotherapy Versus Conventionally Fractionated Radiochemotherapy for Unresectable Head-and-Neck Cancer

  2021cites this paper
• Hyperfractionated concurrent chemoradiation against conventional concurrent chemoradiation in locally advanced head and neck carcinoma: a prospective randomised trial

  2021cites this paper
• Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522.

  2021cites this paper
• Customized 3D Bolus Applied to the Oral Cavity and Supraclavicular Area for Head and Neck Cancer

  2021cites this paper
• Patient-Reported Outcomes after Intensity-Modulated Proton Therapy for Oropharynx Cancer

  2021cites this paper
• Comparison of Conventional Fractionation and Accelerated Fractionation With Concomitant Boost for Radiotherapy of Non-metastatic Stage IV Head-and-Neck Cancer

  2021cites this paper
• Kurative Radiochemotherapie von Kopf-Hals-Tumoren

  2021cites this paper
• Split-course hypofractionated radiotherapy for aged and frail patients with head and neck cancers. A retrospective study of 75 cases.

  2020cites this paper
• Locally Advanced Squamous Cell Carcinoma

  2020cites this paper
• Comparison of altered fractionation schedule with concurrent chemo-radiation for squamous cell carcinoma of head and neck

  2020cites this paper
• The association between cumulative radiation dose and the incidence of severe oral mucositis in head and neck cancers during radiotherapy

  2020cites this paper
• Demonstration of bystander response in high dose technique of grid using theoretical calculation by linear quadratic model along with experimental investigations

  2020cites this paper
• Radiation Therapy Oncology Group

  2020cites this paper
• The role of concomitant chemoradiotherapy in AJCC 7th edition T1-2N1 oropharyngeal carcinoma in the human papillomavirus era.

  2020cites this paper
• A comparative study of concomitant boost radiation versus concomitant boost with concurrent chemoradiation versus standard fractionation chemoradiation in locally advanced head-and-neck cancer

  2020cites this paper
• Impact of Treatment Time on Outcome for Resected Head and Neck Squamous Cell Carcinoma by HPV Status

  2020cites this paper
• Optimizing Treatment De-Escalation in Head and Neck Cancer: Current and Future Perspectives.

  2020cites this paper
• Lower pretreatment hemoglobin status and treatment breaks in locally advanced head and neck squamous cell carcinoma during concurrent chemoradiation

  2020cites this paper
• Most Cited Articles in Head and Neck Oncology

  2020cites this paper
• Differences in lower cranial nerve complications predicted by the NTCP model between RTOG and reduced-volume IMRT planning in radiotherapy for nasopharyngeal carcinoma

  2020cites this paper
• A prospective study to compare conventional radiotherapy verses accelerated radiotherapy with concurrent chemotherapy in squamous cell carcinoma of oral cavity

  2020cites this paper
• Radiation resistance in head and neck squamous cell carcinoma: dire need for an appropriate sensitizer

  2020cites this paper
• Optimal Dose of Cisplatin (CDDP) Given Concurrently with Radiotherapy (RT) in Locally Advanced Squamous Cell Head and Neck Cancer (SQC HNC)

  2020cites this paper
• Response to hyperfractionated accelerated radiotherapy in chemotherapy-refractory non-Hodgkin lymphoma

  2020cites this paper
• DAHANCA 28: A phase I/II feasibility study of hyperfractionated, accelerated radiotherapy with concomitant cisplatin and nimorazole (HART-CN) for patients with locally advanced, HPV/p16-negative squamous cell carcinoma of the oropharynx, hypopharynx, larynx and oral cavity.

  2020cites this paper
• The Evolving Role of Radiotherapy for Head and Neck Cancer.

  2020cites this paper
• Long-Term Update of NRG Oncology RTOG 0522: A Randomized Phase III Trial of Concurrent Radiation and Cisplatin with or without Cetuximab in Locoregionally Advanced Head and Neck Cancer

  2020cites this paper
• Cancer of the Head and Neck

  2020cites this paper
• Factors Impacting Differential Outcomes in the Definitive Radiation Treatment of Anal Cancer Between HIV-Positive and HIV-Negative Patients.

  2020cites this paper